ASX 200 healthcare share Clarity Pharmaceuticals Ltd (ASX: CU6) is the worst performer of the S&P/ASX 200 Index (ASX: XJO) on Tuesday.
Clarity Pharmaceuticals shares fell 9.84% to an intraday low of $2.84 in early trading today.
The company has since recovered some ground and is now trading at $2.99, down 5.08%.
What's going on?
ASX 200 healthcare share in poor shape on Tuesday
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing new diagnostic tools and treatments for children and adults with various forms of cancer.
There is no official news from the company today.
However, the ASX 200 healthcare share has struggled since the company dropped its 1H FY25 results just before the market close last Friday.
We saw a strong initial reaction from investors yesterday, with the Clarity Pharmaceuticals share price falling 12.15% to close at $3.15.
Today, it seems the market is continuing to punish the stock.
Let's check out the details of the report.
Clarity's 1H FY25 results lead to big drop in share price
For the six months ended 31 December, Clarity reported a $23.5 million loss after tax. That's up from a $17.2 million loss for 1H FY24.
Management said the higher loss reflected increased research and development costs, which were $8.9 million higher at $28.6 million for the half.
This follows an increase in clinical trial work.
Clarity says it has a 'cash runway through to mid 2026', which will allow it to continue running and expanding its trials.
It's got $111.2 million in the bank and expects an FY24 research and development tax incentive to provide another $11 million in funds.
Clarity Pharmaceuticals has three lead products, SAR-bisPSMA, SAR-Bombesin, and SARTATE. All three are theranostic products, meaning they have diagnostic and treatment applications.
The lead products are currently progressing through eight clinical trials, including three theranostic trials and five diagnostic trials.
SAR-bisPSMA is a prostate cancer product. It's being tested via the SECuRE, AMPLIFY, CLARIFY, and COBRA trials.
SAR-Bombesin is also a prostate cancer product. It's being examined in the COMBAT, SABRE, and BOP trials.
SARTATE is a paediatric cancer product for the treatment and management of high-risk neuroblastoma, and the management of Neuroendocrine Tumours (NETs). SARTATE's CL04 and DISCO trials are ongoing.
What does management say?
Dr Alan Taylor, executive chair, describes Clarity Pharmaceuticals as an "incredible Australian science success story".
In a statement regarding the first half of 2025, Dr Taylor said:
Nothing represents our feats in science to date more than receiving 3 Fast Track Designations (FTDs) in 6 months for the one molecule, SAR bisPSMA, an accomplishment we believe is unprecedented.
These designations are provided by the United States (US) Food and Drug Administration (FDA) for high unmet need indications and are very difficult to achieve.
It is extraordinary to receive 3 in just 6 months, highlighting the critical need for novel diagnostics and therapies in prostate cancer and our unique position with one molecule in this large indication representing a market valued well in excess of tens of billions of dollars annually.
What's next for the ASX 200 healthcare share?
Dr Taylor said the ASX 200 healthcare company would share further news on the SECuRE trial's progress this month after the completion of Cohort 4.
The current consensus rating on Clarity Pharmaceuticals shares among brokers on CommSec is a 'strong buy'.
Of the four analysts rating the stock, three say it's a strong buy, and one says it's a moderate buy.
